Amgen Pulled Up Over Anti-Biosimilar Pegfilgrastim Promotion
FDA Cautions Originator Over ‘Misleading’ Claims On Neulasta Onpro
Amgen has been rebuked by the FDA over promotion for its unique Neulasta Onpro on-body injector version of pegfilgrastim, in which the firm made false or misleading claims about its benefit compared to a pre-filled syringe formulation of pegfilgrastim, where biosimilar competition exists.
